NAUT vs. TNYA, BCAB, TALS, ORIC, AFMD, LAB, CTKB, QTRX, EYPT, and PACB
Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Tenaya Therapeutics (TNYA), BioAtla (BCAB), Talaris Therapeutics (TALS), ORIC Pharmaceuticals (ORIC), Affimed (AFMD), Standard BioTools (LAB), Cytek Biosciences (CTKB), Quanterix (QTRX), EyePoint Pharmaceuticals (EYPT), and Pacific Biosciences of California (PACB). These companies are all part of the "medical" sector.
Tenaya Therapeutics (NASDAQ:TNYA) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.
Tenaya Therapeutics has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.
Tenaya Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 262.32%. Nautilus Biotechnology has a consensus target price of $6.00, suggesting a potential upside of 132.56%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Tenaya Therapeutics is more favorable than Nautilus Biotechnology.
90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 32.8% of Tenaya Therapeutics shares are held by insiders. Comparatively, 40.5% of Nautilus Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tenaya Therapeutics received 22 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 75.76% of users gave Tenaya Therapeutics an outperform vote while only 16.67% of users gave Nautilus Biotechnology an outperform vote.
Tenaya Therapeutics' return on equity of -24.94% beat Nautilus Biotechnology's return on equity.
In the previous week, Tenaya Therapeutics had 1 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 2 mentions for Nautilus Biotechnology. Tenaya Therapeutics' average media sentiment score of 1.88 beat Nautilus Biotechnology's score of 0.98 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.
Summary
Tenaya Therapeutics beats Nautilus Biotechnology on 9 of the 15 factors compared between the two stocks.
Get Nautilus Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nautilus Biotechnology Competitors List
Related Companies and Tools
